Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Conditions: Primary Central Nervous System Lymphoma Interventions: Procedure: Cognitive Assessment; Biological: Obinutuzumab; Other: Quality of Life Assessment Sponsors: Providence Health& Services Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials